Under the agreement, Intercell will receive upfront, option and payments as well as royalties on product net sales.

Gerd Zettlmeissl, CEO of Intercell, said: “Having partnered a number of our vaccine candidates derived from our AIP with human vaccine players such as Merck and Novartis, we are very pleased to leverage the value of this technology also with a major animal vaccine company like Boehringer Ingelheim Vertmedica.”

Joachim Hasenmaier, CEO of Boehringer Ingelheim Vetmedica, said: “We are pleased to partner with Intercell and to gain access to attractive vaccine targets generated by AIP. We are committed to develop innovative vaccines to meet the urgent needs for the benefit of animal health.”

How far the agreement will help to develop animal vaccines?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.